November 30, 2021SHILAP Revista de lepidopterología45 citationsOpen Access

Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by 64CuCu-DOTATATE PET/CT: Results from the LIRAFLAME Trial

JJJacob K. JensenUniversity of Copenhagen EZEmilie H. ZobelSteno Diabetes Centers BSBernt Johan von ScholtenNovo Nordisk (Denmark)

Structured PICO

Does liraglutide reduce coronary artery inflammation quantified by [64Cu]Cu-DOTATATE PET/CT in patients with Type 2 Diabetes?

Population

Patients with Type 2 Diabetes

Intervention

Liraglutide treatment for 26 weeks

Comparator

Placebo

Outcome

Coronary artery inflammation quantified by [64Cu]Cu-DOTATATE PET/CT uptakesurrogate

Liraglutide treatment for 26 weeks significantly reduces coronary artery inflammation in patients with type 2 diabetes, providing a potential mechanism for its cardiovascular benefits.

Abstract

Liraglutide treatment for 26-weeks caused a significant reduction in 64CuCu-DOTATATE uptake in the coronary arteries whereas this was not seen in the placebo treated group. In addition, 64CuCu-DOTATATE PET/CT as a marker of coronary inflammation correlated with the systemic inflammation marker hs-CRP.

Ask AI

Helpful

Bookmark

View Full Paper